Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Novo Nordisk (NYSE: NVO) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic, Rybelsus, Saxenda, and Wegovy.
While Ozempic is approved by the Food and Drug Administration (FDA) to treat diabetes patients, its sibling medicine Wegovy is prescribed for obesity care. Just this week, Novo Nordisk received some very good news regarding Wegovy. Let's dig into the company's latest milestone and assess what it could mean for future growth.
Although Ozempic is Novo Nordisk's current crown jewel, Wegovy is quickly becoming a force on its own. Earlier this year, investors learned that sales of Wegovy rose 393% year over year in 2023. And that was just in the U.S.
Source Fool.com
